Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October ...

Why Wall Street loves Lilly. So what does this Wall Street analyst like about Lilly? Yesterday, Eli Lilly announced it will ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

Can Eli Lilly (NYSE: LLY) stock surge 2x to $2,000 in the coming years? We believe that this is indeed a genuine possibility.

Eli Lilly stock trades for more than $900 per share, which may appear expensive upon first glance.

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, ...

Eli Lilly and Novo Nordisk are fighting to capture the weight-loss drug market. Amazon could complicate things.

After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of ...

A deal could be reached as soon as Monday and could include additional payments tied to Kelonia meeting certain milestones, ...

Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started ...

Eli Lilly (LLY) stock is in focus as the company agrees to buy cancer drug develoer Kelonia Therapeutics for up to $7B in ...